A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

Manuela Tiako Meyo,1,2 Jeanne Chen,1,2 Francois Goldwasser,1,2 Laure Hirsch,1,2 Olivier Huillard1,2 1Department of Medical Oncology, Institut du Cancer Paris CARPEM, AP-HP, APHP.Centre, Hôpital Cochin, Paris, France; 2Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), AP-HP, APHP.Cen...

Full description

Bibliographic Details
Main Authors: Tiako Meyo M, Chen J, Goldwasser F, Hirsch L, Huillard O
Format: Article
Language:English
Published: Dove Medical Press 2022-07-01
Series:Therapeutics and Clinical Risk Management
Subjects:
renal cell carcinoma
vascular endothelial growth factor
immune checkpoint inhibitor
axitinib
avelumab
pharmacology
Online Access:https://www.dovepress.com/a-profile-of-avelumab-plus-axitinib-in-the-treatment-of-renal-cell-car-peer-reviewed-fulltext-article-TCRM

Internet

https://www.dovepress.com/a-profile-of-avelumab-plus-axitinib-in-the-treatment-of-renal-cell-car-peer-reviewed-fulltext-article-TCRM

Similar Items